Monitoring Progress and Adjusting Your GLP-1 Treatment Plan Effective monitoring is essential to assess treatment response, identify potential complications, and optimise outcomes with GLP-1 receptor agonist therapy
Medical progress: Acromegaly
Rights and permissions About this article Cite this article Dwivedi, D., Megha, K., Mishra, R
In men, this can lead to: Spontaneous erections Prolonged or painful erections (priapism), which is a medical emergency and can cause permanent damage if not treated promptly Contamination and Injection Risks Because these products are often manufactured in unregulated environments: There is a high risk of contamination or impurities Dosing may be inaccurate Injection use increases the risk of infection There is no guarantee of what the product actually contains, which adds another layer of risk
FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) do not contain niacinamide or any other additive
While they usually improve with time, about 1 in 10 people ultimately stop taking semaglutide due to side effects
